CAMBRIDGE, Mass., April 25, 2018 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ:BPMC), a leader in discovering and
developing targeted kinase medicines for patients with genomically
defined diseases, today announced that it will host a live
conference call and webcast at 8:30 a.m. ET
on Wednesday, May 2, 2018 to report its first quarter 2018
financial results and provide a corporate update.
To access the live conference call, please dial 1-855-728-4793
(domestic) or 1-503-343-6666 (international), and refer to
conference ID 7572918. A webcast of the call will also be available
under "Events and Presentations" in the Investors section of the
Blueprint Medicines website at http://ir.blueprintmedicines.com/.
The archived webcast will be available on Blueprint Medicines'
website approximately two hours after the conference call and will
be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of targeted
and potent kinase medicines to improve the lives of patients with
genomically defined diseases. Its approach is rooted in a deep
understanding of the genetic blueprint of cancer and other diseases
driven by the abnormal activation of kinases. Blueprint Medicines
is advancing multiple programs in clinical development for subsets
of patients with gastrointestinal stromal tumors, hepatocellular
carcinoma, systemic mastocytosis, non-small cell lung cancer,
medullary thyroid cancer and other advanced solid tumors, as well
as multiple programs in research and preclinical development. For
more information, please visit www.blueprintmedicines.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2018-financial-results-on-wednesday-may-2-2018-300635968.html
SOURCE Blueprint Medicines Corporation